SCHEMBL6035792

SCHEMBL6035792

CCOC(=O)CCc1ccc(O)cc1OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
PTGER1 P34995 1/20 0.47
PTGER4 P35408 1/20 0.47
PTGER3 P43115 1/20 0.47
PTGER2 P43116 1/20 0.47
FFAR4 Q5NUL3 1/20 0.47
ITGB1 P05556 1/20 0.46
ITGA4 P13612 1/20 0.46
ALOX5 P09917 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ELANE P08246 3/20 0.45
F2 P00734 1/20 0.45
ABCB1 P08183 1/20 0.44
APP P05067 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7901019 0.89 FFAR1 (0.51) CYP4F2CYP4A11PTGER1PTGER4PTGER3
SCHEMBL4034507 0.87 CYP4F2 (0.50) CYP4F2CYP4A11KDM4E
SCHEMBL3218781 0.83 L3MBTL1 (0.47) CYP4F2CYP4A11TDP1L3MBTL1APP
SCHEMBL10635313 0.82 CYP4F2 (0.53) CYP4F2CYP4A11FFAR4L3MBTL1LMNA
SCHEMBL28454621 0.82 CYP4F2 (0.53) CYP4F2CYP4A11PTGER1PTGER4PTGER3
SCHEMBL1549816 0.81 CYP4F2 (0.50) CYP4F2CYP4A11F2KDM4E
SCHEMBL2538767 0.81 PTGER4 (0.54) CYP4F2CYP4A11PTGER1PTGER4PTGER3
SCHEMBL6034704 0.80 FFAR4 (0.56) CYP4F2CYP4A11FFAR4ALOX5TDP1
SCHEMBL4953832 0.80 FFAR1 (0.49) PTGER1PTGER4PTGER3PTGER2FFAR4
SCHEMBL8562654 0.79 PTGER1 (0.45) CYP4F2CYP4A11PTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 CYP4F2 90/4885CYP4A11 18/4885PTGER1 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.